. 2017 Aug 16;17:573. doi: 10.1186/s12879-017-2662-8

Table 3.

Predictors of poor treatment outcome (i.e. death or failure), loss to follow-up, and unfavourable outcomes (i.e. death, treatment failure, or loss to follow-up) in patients with multidrug-resistant and extensively drug-resistant tuberculosis in Hunan Province, China, 2011–2014

Variables	Poor treatment outcome		Lost to follow up		Unfavourable outcome
Variables	CHR^b (95% CI)	AHR^c (95% CI)	CHR^b (95% CI)	AHR^c (95% CI)	CHR^b (95% CI)	AHR^c (95% CI)
Age in years	1.0 (0.9–1.0)	1.0 (0.9–1.01)	1.01(1.0–1.03)	1.0 (0.9–1.02)	1.01 (1.0–1.02)	1.01 (1.0–1.02
Male gender	1.2 (0.7–2.0)	1.1 (0.7–1.8)	1.4 (0.9–2.2)	1.4 (0.9–2.1)	1.4 (1.04–2.0)	1.3 (0.97–1.9)
Occupation^a
Labourer	0.5 (0.1–3.1)	0.3 (0.06–2.1)	1.6 (0 .7–3.8)	1.9 (0.8–4.3)	1.2 (0.6–2.7)	1.3 (0.6–2.8)
Employed	0.4 (0.1–3.0)	0.4 (0.05–3.2)	0.6 (0.2–2.0)	0.7 (0.2–2.4)	0.5 (0.2–1.4)	0.6 (0.2–1.5)
Unemployed	2.0 (0.7–4.9)	1.8 (0.7–4.8)	1.1 (0.5–2.)	1.4 (0.6–3.2)	1.5 (0.8–2.7)	1.7 (0.9–3.2)
Other/unknown	1.5 (0.8–2.8)	1.4 (0.7–2.6)	0.9 (0.5–1.6)	1.01 (0.5–1.8)	1.0 (0 .7–1.6)	1.1 (0.7–1.8)
Treatment starting year^a
2011–2012	2.8 (1.5–5.2)	2.8 (1.4–5.0)	0 .6 (0.4–1.1)	0.6 (0.3–1.03)	1.1 (0 .7–1.5)	1.0 (0.7–1.5)
2013	2.1 (1.2–3.8)	2.0 (1.1–3.8)	0 .7 (0 .5–1.1)	0.7 (0.5–1.1)	1.0 (0.7–1.4)	0.9 (0.7–1.4)
Previous anti-TB treatment	1.8 (0.8–4.2)	1.8 (0.8–4.2)	0 .7 (0.5–1.2)	0.8 (0.5–1.2)	0.9 (0.6–1.4)	0.9 (0.6–1.4)
Resistant to Ethambutol	1.2 (0.8–2.0)	1.3 (0.8–2.1)	1.1 (0.7–1.5)	1.1 (0.7–1.6)	1.1 (0.8–1.5)	1.2 (0.9–1.6)
Resistant to second-line injectable drug	1.3 (0.8–2.2)	1.3 (0.8–2.1)	0.7 (0 .4–1.0)	0.7 (0.5–1.02)	0 .8 (0.6–1.1)	1.7 (0.5–5.4)
Resistant to Ofloxacin	2.8 (1.4–5.6)	3.1 (1.5–6.3)	0.9 (0.4–1.8)	1.01 (0.5–2.1)	1.5 (0.9–2.5)	1.7 (1.07–2.9)

^aFor occupation farmer, and for treatment starting year 2014 was the referent category

^bCHR, crude hazard ratio; ^cAHR, adjusted hazard ratio